Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Status:
Terminated
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving pacritinib before standard of
care drugs followed by an allogeneic stem cell transplant can help to control
myeloproliferative neoplasms. The safety of this therapy will also be studied.